Endoscopic Vessel Harvesting System Market: as Getinge's Vasoview Hemopro 3 finally moves from FDA clearance into actual US clinical cases, the platform's real test shifts from a regulatory filing to whether cardiac surgery teams find the smoke evacuation and energy control improvements meaningful enough at the bedside to displace a system that has already reached three million treatments worldwide, so incumbency and clinical familiarity remain the dominant force in this market, and any challenger's path to share runs through demonstrated operating-room performance, not regulatory clearance alone.

The global endoscopic vessel harvesting system market size was USD 524.8 Million in 2025 and is expected to register a revenue CAGR of 3.9% during the forecast period. Market revenue growth is driven by factors such as sustained coronary artery bypass grafting procedure volume, next-generation EVH system clearances improving smoke evacuation and energy control, and clinical evidence supporting endoscopic harvesting's reduced wound complication rate over open vein harvesting. The first driving factor is sustained coronary artery bypass grafting procedure volume, which continues to generate demand for harvested vein and artery conduits despite the growth of percutaneous coronary intervention as an alternative treatment pathway. EVH systems capital equipment account for a substantial share of total 2025 market revenue, reflecting the capital-intensive nature of the harvester and tower hardware underlying this category. The second driving factor is next-generation EVH system clearances that improve smoke evacuation and energy control during the harvesting procedure itself. The third driving factor is accumulating clinical evidence supporting endoscopic vessel harvesting's reduced wound complication rate relative to traditional open vein harvesting technique. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a single EVH platform's installed base of towers and camera systems generates recurring disposable cannula and blade revenue on every subsequent procedure performed on that system, which converts one capital equipment placement into a multi-year recurring consumables revenue stream tied to that hospital's ongoing CABG procedure volume. Because EVH capital equipment is typically compatible only with its own manufacturer's disposable cannulae and blades, a hospital's initial EVH capital purchase decision effectively locks in that manufacturer's consumables revenue for the full service life of the capital equipment, so EVH manufacturer revenue compounds through recurring disposable sales far more than through capital placement alone. As a result, demand and revenue share are concentrated among manufacturers with the deepest existing installed capital equipment base, and the forecast reflects Getinge's substantial incumbency advantage from having already reached three million EVH treatments performed globally using its Vasoview technology. For instance, in the second quarter of 2025, Getinge successfully conducted its first US clinical cases using the Vasoview Hemopro 3 system following its March 2024 FDA 510(k) clearance, extending its already-dominant installed base with a next-generation platform rather than ceding ground to a new entrant. These are some of the key factors driving revenue growth of the market.

Because percutaneous coronary intervention continues to expand as a less invasive alternative to coronary artery bypass grafting for an increasing share of coronary artery disease patients, the underlying surgical CABG procedure volume that drives EVH device demand faces a structural headwind independent of EVH technology's own merits.

Specialist technique training requirements are a second constraint, because endoscopic vessel harvesting requires meaningfully different surgical technique than open vein harvesting, and surgical teams without adequate EVH-specific training may default to the familiar open technique even where EVH offers documented wound complication advantages.

Graft quality and long-term patency concerns are a third constraint, since some clinical literature has raised questions about whether endoscopically harvested vein grafts maintain comparable long-term patency to open-harvested grafts, and this ongoing clinical debate continues to influence surgeon technique preference at some institutions.

These factors substantially limit endoscopic vessel harvesting system market growth over the forecast period.

The clearest driver of demand is the sustained scale of coronary artery bypass grafting procedure volume, which continues to require harvested vein and artery conduits regardless of the broader trend toward less invasive coronary intervention. CABG remains the preferred revascularisation approach for patients with complex multi-vessel coronary artery disease that percutaneous intervention cannot adequately address, so a meaningful and clinically well-defined patient population continues to require surgical bypass and the vessel harvesting it depends on. EVH systems capital equipment account for a substantial share of total 2025 market revenue, and the CDC's documentation of approximately 695,000 US heart disease deaths in 2021 underscores the scale of cardiovascular disease burden underlying sustained CABG demand. The effect on the market is that baseline EVH demand tracks the CABG-eligible patient population specifically, a smaller but more clinically stable base than overall cardiovascular disease incidence. These are some of the key factors driving revenue growth of the market.

The second driver is next-generation EVH system clearances that improve smoke evacuation and energy control during the harvesting procedure, extending established platforms' clinical differentiation. Surgical smoke generated during energy-based vessel harvesting can obscure visualization and expose operating room staff to combustion byproducts, so a system that more effectively evacuates smoke while giving surgeons more precise energy control addresses both a visualization and an occupational safety consideration simultaneously. Getinge received FDA 510(k) clearance for its Vasoview Hemopro 3 EVH system in March 2024, featuring enhanced smoke evacuation and regulated energy control, and successfully conducted its first US clinical cases using the platform in the second quarter of 2025. The effect on the market is that the incumbent manufacturer with the largest installed base is also the one advancing the platform generation, reinforcing rather than disrupting its existing market position. These are some of the key factors driving revenue growth of the market.

Getinge's EVH technology has already reached three million treatments performed globally. The Vasoview Hemopro 3's move from FDA clearance to actual US clinical cases in Q2 2025 extends, rather than challenges, that incumbency.

The third driver is accumulating clinical evidence supporting endoscopic vessel harvesting's reduced wound complication rate relative to traditional open vein harvesting technique. Open vein harvesting requires a long incision along the leg that carries meaningful risk of wound infection, delayed healing, and patient discomfort, so clinical evidence documenting materially lower wound complication rates with endoscopic technique provides an ongoing, non-technology-specific rationale for EVH adoption across any manufacturer's platform. The effect on the market is that this driver supports the category broadly rather than favouring any single manufacturer, sustaining baseline EVH adoption independent of which company's specific platform a given hospital selects. These are some of the key factors driving revenue growth of the market.

However, the endoscopic vessel harvesting system market faces severe adoption constraints from the growth of percutaneous coronary intervention as an alternative to surgical revascularisation and specialist technique training requirements.

Because percutaneous coronary intervention continues to expand as a less invasive alternative to coronary artery bypass grafting for an increasing share of coronary artery disease patients, the underlying surgical CABG procedure volume that drives EVH device demand faces a structural headwind independent of EVH technology's own clinical merits or platform improvements.

Specialist technique training requirements compound this, because endoscopic vessel harvesting requires meaningfully different surgical technique than open vein harvesting, and surgical teams without adequate EVH-specific training may default to the familiar open technique even where EVH offers documented wound complication advantages, particularly at lower-volume cardiac surgery programmes.

Graft quality and long-term patency concerns are the third constraint, since some clinical literature has raised questions about whether endoscopically harvested vein grafts maintain comparable long-term patency to open-harvested grafts, and this ongoing clinical debate continues to influence surgeon technique preference at some institutions despite EVH's wound-complication advantages.

These factors substantially limit endoscopic vessel harvesting system market growth over the forecast period.

Based on product, the global endoscopic vessel harvesting system market is segmented into EVH systems capital equipment, disposable cannulae and blades, and EVH accessories and energy sources. EVH systems capital equipment holds the largest revenue share, because the harvester, tower, and camera system represent the largest single purchase decision in any EVH programme and anchor the recurring consumables relationship that follows, which suits a market where capital equipment placement determines the manufacturer relationship for the equipment's full service life. Disposable cannulae and blades are expected to register the fastest revenue growth rate in the global endoscopic vessel harvesting system market over the forecast period, driven by the recurring, procedure-tied nature of consumables revenue accumulating across an expanding global installed capital equipment base, which is why manufacturer revenue increasingly depends on defending and growing this recurring stream rather than capital placement alone.

Greater saphenous vein vessel type is expected to account for the largest revenue share in the global endoscopic vessel harvesting system market during the forecast period

Based on vessel type, the global endoscopic vessel harvesting system market is segmented into greater saphenous vein and radial artery harvesting. Greater saphenous vein harvesting holds the largest revenue share, because the GSV remains the primary conduit choice for the majority of CABG procedures globally, which ties directly back to the sustained CABG procedure volume described in the market's primary demand driver. Radial artery harvesting is expected to register the fastest revenue growth rate in the global endoscopic vessel harvesting system market over the forecast period, driven by accumulating long-term patency data favouring arterial over venous conduits in certain patient populations, which is why cardiac surgery programmes are increasingly incorporating endoscopic radial artery harvesting alongside traditional GSV technique.

Based on usability, the global endoscopic vessel harvesting system market is segmented into reusable EVH systems and single-use or disposable EVH components. Reusable EVH systems hold the largest revenue share by capital equipment value, because the harvester and camera tower are engineered for extended multi-year service life across many procedures, which suits a market where capital durability supports the recurring consumables revenue model described in the market's primary demand driver. Single-use and disposable EVH components register steady, procedure-tied revenue growth in line with overall CABG procedure volume, reflecting their role as the recurring consumable half of the capital-plus-consumables EVH business model.

Based on regional analysis, the endoscopic vessel harvesting system market in North America accounted for largest revenue share in 2025. The United States leads because the concentration of high-volume cardiac surgery programmes and established EVH training infrastructure sustains the largest installed capital equipment base globally, and because Getinge's first US clinical cases for the Vasoview Hemopro 3 in the second quarter of 2025 specifically reinforce the country's position as the platform's primary commercial market. The scale of the US CABG procedure volume anchors a domestic EVH consumables market large enough to sustain the recurring revenue model that underpins manufacturer economics in this category. The concentration of FDA clearance activity in the country also means new EVH platform generations are typically launched in the United States first, before expanding to other regulatory jurisdictions.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, the United Kingdom, and France represent the three largest national markets within Europe. Getinge, headquartered in Sweden, maintains its primary global manufacturing and commercial base in Europe alongside its established cardiac surgery clinical relationships. The result is steady rather than rapid growth, shaped more by national health system cardiac surgery capacity than by underlying patient demand.

The market in Asia Pacific is expected to register a moderate to steady revenue growth rate over the forecast period. Japan and China represent the two largest national markets within the region, driven by expanding cardiac surgery capacity even as percutaneous intervention adoption also grows rapidly across the region. Terumo Cardiovascular's manufacturing presence supports the broader Asia Pacific cardiovascular device supply chain relevant to this market.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national markets within the region, with Terumo Cardiovascular's Costa Rica manufacturing facility, opened in September 2022, specifically supporting Americas cardiovascular device supply. The ongoing Iran-US sanctions and the resulting Strait of Hormuz shipping disruption have raised freight and import costs for the specialised camera and energy delivery components that Latin American device distributors depend on, an effect expected to run through 2026 and slow endoscopic vessel harvesting system adoption beyond Brazil's and Mexico's main cardiac surgery centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial markets within the region. Saudi Arabia's expanding cardiac surgery capacity and the UAE's regional medical tourism positioning represent the primary investment centres for endoscopic vessel harvesting system adoption. Saudi Arabia is the most established market on the continent, while the Gulf states outside it are still building the specialist cardiac surgery training infrastructure needed to support EVH adoption at scale.